---
title: Organoid Model Development Know How
description: Learn how we create patient-derived organoid models that can be applied to your large scale drug screen
image: https://resources.huborganoids.nl/hubfs/model%20dev%20-%20drug%20dev%20-%20LI%20(1).jpg
---

[![Logo HUB Organoids](https://resources.huborganoids.nl/hubfs/raw_assets/public/HUBOrganoids_May2021/images/logo-huborganoids-white.svg "Logo HUB Organoids")](https://huborganoids.nl/)

![merk-m-logo-blue](https://resources.huborganoids.nl/hs-fs/hubfs/merk-m-logo-blue.png?width=728&height=225&name=merk-m-logo-blue.png)

# Work with the pioneers of Organoid Technology and get patient-derived data for research program

Our proprietary technology allows you to develop *“mini-organs in a dish”* derived from patient tissues that can recapitulate your research questions in a patient-relevant model and support the development of promising lead candidates in the preclinical phase before you move to clinical trials. 

## Why choose Organoids?

- Derived from adult stem cells
- Physiologically relevant
- Genetically and phenotypically stable
- High predictive value of patient response

![](https://www.huborganoids.nl/wp-content/uploads/2023/08/key-hub-organoid-features2.png)![](https://www.huborganoids.nl/wp-content/uploads/2023/08/mobile-img.png)

- Expandable for large-scale screens
- Suitable for genetic manipulation
- High establishment efficiency

## Seamlessly go from patient tissue to organoid culture

Our end-to-end process transforms patient biopsies into validated, expandable models that accelerate drug discovery and translational research.

 

## From hypothesis to hits: identify new therapeutic opportunities

Enhance translational relevance from the start of your drug development process. With deep expertise in organoid monolayers and 3D co-culture models integrating multiple cell types, we enable robust, physiologically relevant assays to identify and validate promising leads for clinical progression.

 

## Discover the science

<https://resources.huborganoids.nl/case-study-drug-discovery-to-clinical-trials-in-five-years>

### CASE STUDY

Drug discovery to clinical trials in five years

[download now](https://resources.huborganoids.nl/case-study-drug-discovery-to-clinical-trials-in-five-years)

<https://resources.huborganoids.nl/license-hub-organoid-technology>

### FACTSHEET

License HUB Organoid Technology

[download now](https://resources.huborganoids.nl/license-hub-organoid-technology)

<https://resources.huborganoids.nl/10-years-of-breakthroughs-in-organoid-technology>

### ON-DEMAND WEBINAR

Watch our CEO present a decade of innovations in Organoid Technology

[watch now](https://resources.huborganoids.nl/10-years-of-breakthroughs-in-organoid-technology)

×

### Download poster

![Logo HUB Organoids](https://resources.huborganoids.nl/hubfs/raw_assets/public/HUBOrganoids_May2021/images/logo-huborganoids-white.svg "Logo HUB Organoids")

[Privacy Policy](https://huborganoids.nl/privacy-policy)

HUB Organoids is now part of the Life Science Business of Merck KGaA, Darmstadt, Germany

***FOR RESEARCH USE ONLY.**  Unless otherwise stated in our catalog or other company documentation  
 accompanying the product(s), our products are intended for research use only and are not to be used   
 for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro   
 diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to   
humans or animals.*